Literature DB >> 31522131

Trends in disability-adjusted life years of lung cancer among women from 2004 to 2030 in Guangzhou, China: A population-based study.

Xiao Lin1, Michael S Bloom2, Zhicheng Du1, Yuantao Hao3.   

Abstract

BACKGROUND: Forecast of disease burden in lung cancer is an important health agenda. One of the main challenges is to predict the evolution of trends in disability-adjusted life year (DALY) of lung cancer so as to anticipate the future burden and to coordinate the supply of sufficient health services and care.
METHODS: Using 2004-2013 cancer registry data in Guangzhou, we fitted Bayesian age-period-cohort models with age, period, and cohort effects to analyze trends of lung cancer among women, and then made forecast for DALY of lung cancer until 2030.
RESULTS: During 2004-2013, there was an annual average of 10,582 DALYs for lung cancer (15.84% of total DALY). In 2014-2030, DALY is expected to reach 234,752 person-years for lung cancer (12.25% of total DALY), with an annual mean of 13,809 DALYs. Lung cancer crude DALY rate is projected to rise steadily from 257.56 (95% uncertainty interval: 165.97-361.22) in 2014 to 316.99 (219.96-419.41) per 100,000 women in 2030, and the rise is mainly seen in 45-64 years age group. Lung cancer DALY rate remains the highest in the 65-89 years age group.
CONCLUSIONS: Women at 65-89 years carry the highest lung cancer burden among other age groups in Guangzhou. The DALY rate of lung cancer is projected to increase most precipitously for the 45-64 years age group. This indicates that concerted efforts are needed to develop adequate cancer services, and to reassess health resources for control and care of lung cancer in these populations.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bayesian age-period-cohort models; Disability-adjusted life year; Disease burden; Forecast; Lung cancer

Year:  2019        PMID: 31522131     DOI: 10.1016/j.canep.2019.101586

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  1 in total

1.  HMGB1 Promotes the Proliferation and Metastasis of Lung Cancer by Activating the Wnt/β-Catenin Pathway.

Authors:  Xiao-Hui Wang; Shu-Ying Zhang; Mei Shi; Xiao-Peng Xu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.